Advertisement

Search Results

Advertisement



Your search for AT matches 29239 pages

Showing 51 - 100


breast cancer

Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers

Incidence rates for invasive lobular carcinoma have increased more drastically than all other breast cancers combined between 2012 and 2021, according to findings from the American Cancer Society’s Lobular Breast Cancer Statistics 2025 report, published in Cancer.  “Although lobular breast cancer...

breast cancer
survivorship

Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer

In a prospective cohort study published in JCO Oncology Practice, Ssebyala et al examined long-term health-care utilization and adherence to follow-up care among young adult survivors of breast cancer. Their findings reveal high rates of mammography adherence but persistent gaps in other areas of...

leukemia

Ziftomenib in Relapsed or Refractory NPM1-Mutant AML

As reported in the Journal of Clinical Oncology by Wang et al, a phase I/II trial (KOMET-001) has shown activity of the oral menin inhibitor ziftomenib in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Study Details In the phase II portion of the trial, 92 patients...

colorectal cancer

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the...

cost of care

Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer

Patients with cancer who developed financial toxicity and falling credit scores faced higher mortality risks, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the Journal of the American College of Surgeons. “Our work...

gastroesophageal cancer
hepatobiliary cancer
colorectal cancer
pancreatic cancer

Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression

New research revealed that depression can impact surgical outcomes, making it more difficult for patients to recover from surgery, thus leading to higher postoperative costs as well. In patients with gastrointestinal cancers and depression who were undergoing surgery specifically, antidepressants...

pancreatic cancer

John L. Cameron, MD, FACS, Receives Wangensteen Scientific Forum Award

John L. Cameron, MD, FACS, a surgeon who radically improved the mortality rates of the Whipple procedure, was honored with the American College of Surgeons (ACS) Owen H. Wangensteen Scientific Forum Award at the ACS Clinical Congress 2025 in Chicago. The award recognizes a surgeon who exemplifies...

breast cancer

Mastectomy Linked to Worsened Sexual Health and Body Image After Surgery, Study Finds

Although mastectomy is often a necessary and life-saving treatment option for many women with breast cancer, the surgery may contribute to worse sexual health, body image, and several other physical and emotional challenges after surgery, according to a recent systematic review on the effects of...

issues in oncology

Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas

When seeking a surgeon for treatment, providing emotional support and helping patients manage expectations are among the top areas of communication valued by patients, according to a recent systematic review. The research was presented at the 2025 American College of Surgeons (ACS) Clinical...

issues in oncology

Considerations on Cancer Drug Development

In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....

lung cancer

FANSS: Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?

The results of the multicenter Female Asian Nonsmoker Screening Study (FANSS) suggest that low-dose CT screening is feasible and has value for early lung cancer detection in the historically underserved demographic of Asian women with no history of smoking. These data from the largest United...

skin cancer

PD-1 Inhibitor Approved for Adjuvant Treatment of CSCC

On October 8, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation therapy. C-POST Efficacy was evaluated in C-POST (ClinicalTrials.gov ...

palliative care

Systemic Anticancer Therapy at End of Life and Health-Care Use Among Older Patients

In a linked Surveillance, Epidemiology, and End Results (SEER)–Medicare analysis reported in the Journal of Clinical Oncology, Canavan et al found that receipt of systemic anticancer therapy (SACT) at the end of life (EOL) was associated with higher rates of EOL emergency department (ED) use,...

leukemia
immunotherapy

Inotuzumab Ozogamicin Followed by Blinatumomab in Older Patients With Newly Diagnosed B-Cell ALL

As reported in the Journal of Clinical Oncology by Wieduwilt et al, findings in a cohort of the phase II Alliance study A041703 indicate that the chemotherapy-free regimen of inotuzumab ozogamicin followed by blinatumomab was highly active in patients aged ≥ 60 years with newly diagnosed B-cell...

breast cancer

Inflammatory Activity and Cancer-Related Fatigue in Early Breast Cancer

Research published in Cancer revealed that inflammatory responses may be tied to cancer-related fatigue and certain inflammatory activities may lead to distinct dimensions of fatigue in women with early-stage breast cancer.  “Our findings indicate that inflammation plays a role in some aspects of...

lung cancer

Improved Outcomes Reported With Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC

In the phase III HARMONi trial, when ivonescimab was given with carboplatin plus pemetrexed, vs the chemotherapy regimen alone, after a third-generation tyrosine kinase inhibitor, patients with EGFR-mutated non–small cell lung cancer (NSCLC) had a significant delay in disease progression.1...

gastroesophageal cancer
lung cancer

Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC

Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...

breast cancer

Predicting Future Breast Cancer Outcomes: Efficacy of a Polygenic Risk Score

Studies show that if left untreated, between 20% and 40% of ductal carcinoma in situ (DCIS) lesions may evolve into invasive breast cancer over time. And, according to the American Cancer Society, women diagnosed with lobular carcinoma in situ (LCIS) have between a 7 and 12 times higher risk of...

hematologic malignancies
geriatric oncology

Immunogenicity of RSV Vaccines in Immunocompromised Allogeneic HSCT Recipients

In patients rendered immunocompromised by allogeneic hematopoietic stem cell transplantation (HSCT), a single dose of the respiratory syncytial virus (RSV) vaccine within the first year afterward resulted in low seroconversion rates, as reported by Redjoul et al in JAMA Network Open. However, a...

issues in oncology

Prior Authorization Is Burdensome for Patients and Results in Treatment Delays, Financial Strain, and Stress, Survey Finds

The process of obtaining insurance prior authorization before a medical procedure, service, or medication prescription has typically been left to clinicians. However, as cancer therapies grow increasingly complex, the burden of navigating insurance prior authorization is increasingly being shared...

issues in oncology

Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers

Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatments, including biologics or radiation therapy. An analysis by Joseph M. Unger, PhD, MS, Professor,...

issues in oncology

Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste

A new study found that implementing a network of cancer drug repositories (CDRs) improved access to cancer medications and eliminated unnecessary medication waste by allowing people to donate unopened or unused medications that would otherwise be wasted. This resulted in patients with cancer...

breast cancer

Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy

No significant differences were observed in breast volume loss between five-fraction whole-breast and partial-breast radiation therapy in patients with breast cancer who underwent prior partial mastectomy, according to the results of a study presented in a poster during the American Society for...

multiple myeloma

Dexamethasone-Sparing Regimen for Frail Patients With Newly Diagnosed Multiple Myeloma

In a French phase III trial (IFM2017-03) reported in The Lancet Oncology, Manier et al found that a dexamethasone-sparing regimen of daratumumab plus lenalidomide improved progression-free survival vs lenalidomide plus dexamethasone in patients with frailty and newly diagnosed multiple myeloma....

lung cancer

Immunotherapy Addition Yields QOL Benefits in Limited-Stage Small Cell Lung Cancer

Clinically meaningful improvements in longer-term quality of life were achieved with the addition of atezolizumab immunotherapy to chemoradiation in patients with limited-stage small cell lung cancer (LS-SCLC), according to patient-reported outcome findings from the NRG LU005 trial presented during ...

issues in oncology

Patient-Reported Outcomes and Overall Survival in Cancer

In a systematic review and meta-analysis reported in JAMA Oncology, Huang et al found that patient-reported outcomes (PROs) provide prognostic information for overall survival in patients with cancer. Study Details  A systematic review of studies published between January 2000 and June 2024 was...

cns cancers

Dose-Intensified Proton Therapy for Newly Diagnosed Glioblastoma

Dose intensification of proton radiation therapy led to improved overall survival for patients with newly diagnosed glioblastoma, according to findings from a cohort of the phase II NRG-BN001 trial, which were presented as late-breaking research during the 2025 American Society for Radiation...

hematologic malignancies
leukemia

9/11 First Responder Study Shows How Toxic Exposures May Lead to Blood Cancers

A recent study has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against...

leukemia

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...

leukemia

Cytogenetic Remission Linked to Improved Survival in Patients With AML

Patients with acute myeloid leukemia (AML) who achieve cytogenetic remission may have better survival outcomes than patients with new or sustained cytogenetic abnormalities, according to findings from a study published in the American Journal of Hematology.  The study elucidated how cytogenetic...

issues in oncology

Medicare Telehealth Flexibilities and CMS Operations During Government Shutdown

The U.S. government shut down on October 1 after lawmakers were unable to reach a funding agreement. The date also marked the deadline to extend the Medicare telehealth flexibilities that have been in place since the COVID-19 public health emergency (PHE). As such, telehealth flexibilities have...

lung cancer

FDA Approves Combination Regimen for Extensive-Stage SCLC

On October 2, the U.S. Food and Drug Administration (FDA) approved lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for maintenance treatment of adults with extensive-stage small cell lung cancer (SCLC) whose disease...

solid tumors

Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

In a Brazilian phase II trial (HERCULES; LACOG 0218) reported in JAMA Oncology, Maluf et al found that pembrolizumab plus platinum-based chemotherapy showed activity in patients with advanced penile squamous cell carcinoma. The investigators explained, “Advanced penile squamous cell carcinoma is...

colorectal cancer
immunotherapy

CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis

Studies show that individuals diagnosed with ulcerative colitis have approximately a twofold increased risk of developing colorectal cancer compared with the general population. A study investigating treatment with autologous chimeric antigen receptor (CAR) T cells targeting the CD19 antigen in a...

lung cancer

In Extensive-Stage Small Cell Lung Cancer, Novel Maintenance Regimen Boosts Overall Survival

The phase Ib DeLLphi-303 trial has reported overall survival data for a novel maintenance regimen in extensive-stage small cell lung cancer following first-line chemoimmunotherapy. Patients treated with the bispecific T-cell engager tarlatamab-dlle plus a PD-L1 inhibitor had a median overall...

sarcoma

CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas

For patients with recurrent retroperitoneal sarcomas that cannot be treated surgically, treatment choices are limited. These tumors can grow in the abdomen adjacent to vital organs or enmeshed within the bowel. Given their radioresistant nature, they require high doses of radiation that risk...

lung cancer

Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

In a phase II trial (WU-KONG1B) reported in the Journal of Clinical Oncology, Yang et al found that the EGFR tyrosine kinase inhibitor sunvozertinib was active at both dose levels tested in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations....

prostate cancer

Variation in PSA Levels in Annual Testing Among Individuals Without a Prostate Cancer Diagnosis

In a study reported in JAMA Oncology, Pickersgill et al found that individuals without prostate cancer undergoing annual prostate-specific antigen (PSA) testing often exhibited a PSA level below biopsy threshold in the year following an elevated test result. Study Details The study involved data on ...

kidney cancer

Kidney Cancer Cases Expected to Double by 2050

Projected cases of kidney cancer are expected to double by 2050 due to modifiable risk factors, according to findings and estimations published in European Urology.   “Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for this steep rise,” stated ...

breast cancer

Impact of Proton and Photon Therapies on HRQOL in Breast Cancer

Health-related quality-of-life measurements demonstrated that both proton and photon radiation therapies led to excellent and similar impacts on quality of life for patients with breast cancer undergoing comprehensive nodal irradiation, according to findings from the phase III RadComp trial that...

prostate cancer

Intermediate-Risk Prostate Cancer: Shorter Radiation Improves Patient Experience, But Not Disease Control

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation...

head and neck cancer

Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy

A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...

lung cancer

SABR May Be Comparable to Surgery for Early-Stage NSCLC

Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...

bladder cancer

Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer

Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...

lung cancer

Patrick Goodley, MBBChir, MRCP: What Is the Optimal Upper Age Limit for Lung Cancer Screening?

Patrick Goodley, MBBChir, MRCP, of Manchester University NHS Foundation Trust, reports results from a study that looked at treatment and survival rates in people aged 75 to 80 years diagnosed with screen-detected lung cancer in two targeted lung cancer screening implementation settings (Abstract...

prostate cancer

PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide

Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, according to findings from the phase II BALANCE trial (NRG GU006) presented in a press briefing...

prostate cancer

Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease

A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone. The phase II LUNAR trial is the...

Anthony Letai, MD, PhD, Takes the Helm as New NCI Director

Anthony Letai, MD, PhD, was sworn in on September 29 as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), by Health and Human Services Secretary Robert F. Kennedy, Jr. Dr. Letai takes the helm of the world’s most prestigious cancer research agency...

cns cancers

Association of TERT Expression With Outcomes in Meningioma

In an analysis reported in The Lancet Oncology by Gui et al in the International Consortium on Meningiomas, TERT expression in meningiomas was found to be associated with poorer progression-free survival.   Study Details The multi-institutional cohort study involved retrospectively collected data...

hematologic malignancies

Impact of Novel Donor Search Strategy on Outcomes for Potential HCT Recipients

In a study (BMT CTN 1702) reported in the Journal of Clinical Oncology, Lee et al found little difference in 2-year survival outcomes between patients considered “very likely” vs “very unlikely” to find an HLA-matched unrelated donor (MUD) for allogeneic hematopoietic cell transplantation as...

Advertisement

Advertisement




Advertisement